Monitoring Agency Report for the quarter ended March 31, 2026
AMANTA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
CRISIL Ratings Limited has submitted its quarterly monitoring report on Amanta Healthcare's IPO fund utilization for Q4 FY2026. The company raised Rs 12,600 lakhs through its September 2025 IPO. Of the net proceeds of Rs 10,315.19 lakhs, Rs 7,353.25 lakhs (58.4%) has been utilized so far. Rs 4,766.36 lakhs of Rs 7,000 lakhs allocated for SteriPort manufacturing line has been deployed (civil construction and equipment), while Rs 3,013.11 lakhs allocated for the SVP manufacturing line remains completely unutilized due to delays in finalizing supplier terms. General corporate purposes (Rs 302.08 lakhs) and issue expenses (Rs 2,284.81 lakhs) are fully utilized. The unutilized Rs 5,246.75 lakhs is parked in fixed deposits and monitoring accounts. Net proceeds were revised downward by Rs 358.38 lakhs due to higher-than-estimated issue expenses, adjusted from GCP.
The SVP manufacturing line shows zero utilization and the SteriPort line is behind schedule, indicating project delays beyond the prospectus timeline. Investors should monitor whether these manufacturing facilities begin commercial production as planned (SteriPort by FY2026, SVP by FY2027) since delays could affect future revenue growth. The remaining Rs 5,246.75 lakhs in unutilized funds provides capital buffer but raises questions about deployment efficiency.